Related Experiment Video
Updated: Jul 17, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Cisplatin-induced hyperglycemic hyperosmolar coma
R Komdeur1, J Derksen, M-C Legdeur
1Department of Internal Medicine, Medical Spectrum Twente Hospital, Enschede, the Netherlands. R.Komdeur@ziekenhuis-mst.nl
Cisplatin chemotherapy can cause severe high blood sugar and hyperosmolar events, even in patients without diabetes. This rare adverse reaction highlights the need for awareness of cisplatin
Area of Science:
- Oncology
- Endocrinology
- Pharmacology
Background:
- Cisplatin is a widely used platinum-based chemotherapy agent for various solid tumors.
- Adverse drug reactions associated with cisplatin are well-documented, but glucose dysregulation is not commonly recognized.
Observation:
- A case of severe hyperglycemic hyperosmolar derangement is presented following cisplatin treatment.
- The patient had no prior history of diabetes mellitus.
Findings:
- Cisplatin administration can precipitate significant glucose metabolism impairment.
- Hyperglycemic hyperosmolar state is a potential, albeit rare, adverse effect of cisplatin therapy.
Implications:
- Clinicians should be vigilant for glucose abnormalities in patients receiving cisplatin, especially those without pre-existing diabetes.
- Further research is warranted to elucidate the mechanisms and incidence of cisplatin-induced glucose derangement.
- Enhanced monitoring of glycemic control may be necessary during cisplatin chemotherapy.
Related Concept Videos
Hyperosmolar Hyperglycemic State
Hyperglycemia
Hypoglycemia and Glucagon
Hypoglycemia
Diabetes: Symptoms, Diagnosis, and Complications
Diabetic Ketoacidosis l: Introduction
